Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529972 | 1.00 | KMT2A (0.66) | KMT2ATLR2TLR1TPSAB1TPSD1 | |
| SCHEMBL30532196 | 1.00 | KMT2A (0.66) | KMT2ATLR2TLR1TPSAB1TPSD1 | |
| SCHEMBL30532195 | 1.00 | KMT2A (0.66) | KMT2ATLR2TLR1TPSAB1TPSD1 | |
| SCHEMBL5370368 | 0.96 | KMT2A (0.59) | KMT2ATLR2TLR1TPSAB1TPSD1 | |
| SCHEMBL31603929 | 0.92 | KMT2A (0.56) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL15692103 | 0.92 | KMT2A (0.56) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL30905361 | 0.92 | KMT2A (0.56) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL31309796 | 0.87 | KMT2A (0.51) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL83644 | 0.87 | KMT2A (0.51) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL31310023 | 0.87 | KMT2A (0.51) | KMT2ATLR2TLR1EPHX2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20170260232-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-20170260232-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-14 | — | — | US | disclosed |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9688721-B2 | Tubulysin compounds, methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688721-B2 | Tubulysin compounds, methods of making and use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9676794-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2956173-B1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2956173-B1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20140227295-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-14 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014068443-A1 | SPLICEOSTATIN ANALOGS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20130005581-A1 | STRUCTURAL NUCLEIC ACID GUIDED CHEMICAL SYNTHESIS | VIPERGEN APS (DK) | 2013-01-03 | — | — | US | disclosed |
| US-8202823-B2 | Structural nucleic acid guided chemical synthesis | VIPERGEN APS (DK) | 2012-06-19 | — | — | US | disclosed |
| US-8129505-B2 | Formed by catalytic polymerization; antibody conjugates | UCB PHARMA S.A. (BE) | 2012-03-06 | — | — | US | disclosed |
| US-20110045990-A1 | STRUCTURAL NUCLEIC ACID GUIDED CHEMICAL SYNTHESIS | Vipergen Parmaceiticals APS (DK) | 2011-02-24 | — | — | US | disclosed |
| EP-1809743-B1 | STRUCTURAL NUCLEID ACID GUIDED CHEMICAL SYNTHESIS | VIPERGEN APS (DK) | 2008-12-31 | — | — | EP | disclosed |
| EP-1809743-A1 | STRUCTURAL NUCLEID ACID GUIDED CHEMICAL SYNTHESIS | Vipergen APS (DK) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048025-A1 | STRUCTURAL NUCLEIC ACID GUIDED CHEMICAL SYNTHESIS | VIPERGEN APS (DK) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045990-A1 | STRUCTURAL NUCLEIC ACID GUIDED CHEMICAL SYNTHESIS | RNGTT, POLRMT, NSUN3 | KMT2A 3336/4885TLR2 4488/4885TLR1 3929/4885 |
| US-20130005581-A1 | STRUCTURAL NUCLEIC ACID GUIDED CHEMICAL SYNTHESIS | RNGTT, POLRMT, NSUN3 | KMT2A 3358/4885TLR2 4483/4885TLR1 3930/4885 |
| US-20140227295-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | CCNB1, CCNB3, CCNB2 | KMT2A 1192/4885TLR2 4321/4885TLR1 4046/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | KMT2A 1507/4885TLR2 4067/4885TLR1 3545/4885 |
| US-20230277682-A1 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | HAVCR2, VARS1, VIM | KMT2A 694/4885TLR2 1051/4885TLR1 1290/4885 |
| US-20170260232-A1 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE | CCNB1, CCNB3, CCNB2 | KMT2A 1157/4885TLR2 4385/4885TLR1 4113/4885 |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | KMT2A 874/4885TLR2 3406/4885TLR1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.